Cipher Capital LP purchased a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 59,269 shares of the medical instruments supplier’s stock, valued at approximately $1,333,000. Cipher Capital LP owned about 0.10% of OraSure Technologies at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. First Mercantile Trust Co. acquired a new stake in shares of OraSure Technologies during the second quarter worth $104,000. Pinebridge Investments L.P. acquired a new stake in shares of OraSure Technologies during the second quarter worth $131,000. Victory Capital Management Inc. lifted its holdings in shares of OraSure Technologies by 17.6% during the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 1,360 shares in the last quarter. Profund Advisors LLC lifted its holdings in shares of OraSure Technologies by 2.8% during the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 293 shares in the last quarter. Finally, ETRADE Capital Management LLC acquired a new stake in shares of OraSure Technologies during the second quarter worth $193,000. 94.41% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Cipher Capital LP Takes Position in OraSure Technologies, Inc. (OSUR)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/24/cipher-capital-lp-takes-position-in-orasure-technologies-inc-osur.html.

OraSure Technologies, Inc. (NASDAQ OSUR) opened at $16.86 on Friday. The company has a market capitalization of $1,022.53, a PE ratio of 32.42, a P/E/G ratio of 3.24 and a beta of 1.39. OraSure Technologies, Inc. has a 52 week low of $8.21 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million during the quarter, compared to the consensus estimate of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. OraSure Technologies’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 earnings per share. equities research analysts predict that OraSure Technologies, Inc. will post 0.42 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, November 4th. ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Jefferies Group LLC downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $22.00 target price on shares of OraSure Technologies in a report on Tuesday, September 19th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $18.21.

In related news, Director Mara G. Aspinall purchased 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was acquired at an average price of $14.23 per share, with a total value of $71,150.00. Following the completion of the purchase, the director now directly owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,035 shares of company stock valued at $1,297,612. 6.40% of the stock is owned by insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.